534 related articles for article (PubMed ID: 10963635)
1. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
Hutten BA; Prins MH; Gent M; Ginsberg J; Tijssen JG; Büller HR
J Clin Oncol; 2000 Sep; 18(17):3078-83. PubMed ID: 10963635
[TBL] [Abstract][Full Text] [Related]
2. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
[TBL] [Abstract][Full Text] [Related]
3. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
4. Idraparinux versus standard therapy for venous thromboembolic disease.
; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
N Engl J Med; 2007 Sep; 357(11):1094-104. PubMed ID: 17855670
[TBL] [Abstract][Full Text] [Related]
5. Duration of anticoagulation therapy for venous thromboembolism.
Bounameaux H; Perrier A
Hematology Am Soc Hematol Educ Program; 2008; ():252-8. PubMed ID: 19074092
[TBL] [Abstract][Full Text] [Related]
6. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
DeLoughery TG
Crit Care Clin; 2005 Jul; 21(3):497-512. PubMed ID: 15992670
[TBL] [Abstract][Full Text] [Related]
8. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
[TBL] [Abstract][Full Text] [Related]
9. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
Pritchard ER; Murillo JR; Putney D; Hobaugh EC
J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
[TBL] [Abstract][Full Text] [Related]
10. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
[TBL] [Abstract][Full Text] [Related]
11. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.
Dentali F; Pignatelli P; Malato A; Poli D; Di Minno MN; Di Gennaro L; Rancan E; Pastori D; Grifoni E; Squizzato A; Siragusa S; Di Minno G; Ageno W
Am J Hematol; 2012 Apr; 87(4):384-7. PubMed ID: 22367852
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
; Büller HR; Gent M; Gallus AS; Ginsberg J; Prins MH; Baildon R
N Engl J Med; 1997 Sep; 337(10):657-62. PubMed ID: 9280815
[TBL] [Abstract][Full Text] [Related]
13. [The optimal duration of anticoagulant treatment following pulmonary embolism].
Couturaud F
Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
[TBL] [Abstract][Full Text] [Related]
14. Long-term management of patients after venous thromboembolism.
Kearon C
Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
[TBL] [Abstract][Full Text] [Related]
15. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients.
Levine M
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():9-11. PubMed ID: 14730472
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Büller HR; Agnelli G; Hull RD; Hyers TM; Prins MH; Raskob GE
Chest; 2004 Sep; 126(3 Suppl):401S-428S. PubMed ID: 15383479
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van der Heijden JF; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
